Latest Conference Articles

Patient Characteristics Linked to Time on Treatment and Survival in Patients With mCRC Receiving Cetuximab

Patient Characteristics Linked to Time on Treatment and Survival in Patients With mCRC Receiving Cetuximab

June 11th 2021, 6:26pm

KRAS mutational status and geographical region were associated with time on treatment (TOT), and body mass index (BMI) and age were linked with overall survival (OS) in patients with metastatic colorectal cancer mCRC) being treated with second-line cetuximab (Erbitux) after irinotecan or oxaliplatin-based regimens.

Cabozantinib Associated With Higher Rates of Certain AEs in Advanced Kidney Cancer

Cabozantinib Associated With Higher Rates of Certain AEs in Advanced Kidney Cancer

June 11th 2021, 1:28pm

ASCO Annual Meeting

While cabozantinib exposure was not a predictor of progression-free survival, it was related to high rate of palmar-plantar plantar erythrodysesthesia and diarrhea in patients with advanced renal cell carcinoma who are given frontline cabozantinib plus nivolumab.

ASCO 2021: Top Nursing Takeaways

ASCO 2021: Top Nursing Takeaways

June 10th 2021, 4:16pm

ASCO Annual Meeting

This year, there were many takeaways from the American Society of Clinical Oncology Annual Meeting that oncology nurses can incorporate into their practice.

Nurses Have the Responsibility to be the ‘Voice of the Patient’ in Palliative Care Advocacy

Nurses Have the Responsibility to be the ‘Voice of the Patient’ in Palliative Care Advocacy

June 9th 2021, 6:43pm

ASCO Annual Meeting

Learn how to approach palliative care discussions with both physicians and patients.

Bone-Protecting Agents Reduce Fracture Risk During Prostate Cancer Treatment

Bone-Protecting Agents Reduce Fracture Risk During Prostate Cancer Treatment

June 9th 2021, 2:00pm

Men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer who are being treated with radium-223 (Xofigo) plus enzalutamide (Xtandi) can reduce their risk of fractures with the use of bone-protecting agents.

Second-Generation CAR T-Cell Therapy Is ‘Highly Promising’ in Relapsed/Refractory B-NHL

Second-Generation CAR T-Cell Therapy Is ‘Highly Promising’ in Relapsed/Refractory B-NHL

June 8th 2021, 6:30pm

ASCO Annual Meeting

The second-generation 4-1BB bi-specific CAR T-cell therapy was efficacious and safe in treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Sacituzumab Govitecan Beats All Chemo Regimens in TNBC Treatment

Sacituzumab Govitecan Beats All Chemo Regimens in TNBC Treatment

June 8th 2021, 1:31pm

Sacituzumab govitecan, an antibody drug conjugate, maintained survival and response benefits over chemotherapy regimens.

Acalabrutinib: Same Survival Rates, But Better Tolerated Than Ibrutinib in CLL Treatment

Acalabrutinib: Same Survival Rates, But Better Tolerated Than Ibrutinib in CLL Treatment

June 7th 2021, 5:51pm

ASCO Annual Meeting

Survival rates were similar between the 2 drugs, but acalabrutinib had fewer adverse events.

Melanoma Outcomes Are Improved With Nivolumab Alone or With Ipilimumab

Melanoma Outcomes Are Improved With Nivolumab Alone or With Ipilimumab

June 7th 2021, 1:56pm

ASCO Annual Meeting

Nivolumab with or without ipilimumab improved survival over ipilimumab alone in patients with previously untreated advanced melanoma.

Retevmo Shows Improvement for Previously Treated Patients With Non-Small Cell Lung Cancer

Retevmo Shows Improvement for Previously Treated Patients With Non-Small Cell Lung Cancer

June 6th 2021, 7:00pm

ASCO Annual Meeting

Previously treated patients with non-small cell lung cancer tended to have better responses with Retevmo than they did with prior treatments.